Biocon Reports Revenue Growth in Q1 FY27 Financial Results

Biocon Limited reported financial results for the first quarter of FY27, ending June 30, 2026, showing an approximate 10% increase in revenue to 4,336 crore rupees. The growth was driven by a 16% rise in the biosimilars business and a 21% increase in the generics business, though the services business experienced a 16% revenue decline.

Reports differ on the company's net profit for the period. One source states the net profit rose 355% year-on-year to 141 crore rupees, while another reports a 53.36% increase to 136.8 crore rupees.

During the quarter, the company expanded its global commercial presence. Biocon launched Yesafili in the United States and Malaysia, introduced Evfraxy in Europe, and received a Health Canada Notice of Compliance for the Yesintek autoinjector pen.